The public benefit company, born of a partnership of Boston-area universities, hospitals, and private industry led by Harvard and MIT,  named former Orchard Therapeutics, Amgen, and Genzyme executive Ran Zheng its chief executive. Zheng, who started earlier this year, said that the project has been renamed Landmark Bio. It had been called the Center for Advanced Biological Innovation and Manufacturing since it was formed in 2019.

https://news.harvard.edu/gazette/story/2021/07/veteran-biotech-executive-to-run-new-center-for-advanced-cell-manufacturing/